The Analysis of Live-Attenuated Vaccine Reveals the Short-Term Upregulation of Innate and Adaptive Immune Genes in Atlantic Salmon (): An In Situ Open-Sea Cages Study
Overview
Authors
Affiliations
, the etiological agent of the Salmon Rickettsial Septicemia (SRS), is one the most serious health problems for the Chilean salmon industry. Typical antimicrobial strategies used against include antibiotics and vaccines, but these applications have largely failed. A few years ago, the first attenuated-live vaccine against SRS (ALPHA JECT LiVac SRS vaccine) was released to the market. However, there is no data about the agents involved in the activation of the immune response induced under field conditions. Therefore, in this study we evaluated the expression profile of a set of gene markers related to innate and adaptive immunity in the context of a cellular response in Atlantic salmon () reared under productive farm conditions and immunized with a live-attenuated vaccine against . We analyzed the expression at zero, 5-, 15- and 45-days post-vaccination (dpv). Our results reveal that the administration of the attenuated live SRS LiVac vaccine induces a short-term upregulation of the cellular-mediated immune response at 5 dpv modulated by the upregulation of , , and the and T cell surface markers. In addition, we also registered the upregulation of and . Altogether, the results suggest that a balanced activation of the immune response took place only at early times post-vaccination (5 dpv). The scope of this short-term upregulation of the cellular-mediated immune response against a natural outbreak in fish subjected to productive farm conditions deserves further research.
Rozas-Serri M, Pena A, Gardner I, Penaloza E, Maldonado L, Munoz A Pathogens. 2023; 12(3).
PMID: 36986371 PMC: 10053882. DOI: 10.3390/pathogens12030450.
Why vaccines fail against in farmed salmon and trout and how to avoid it: A review.
Valenzuela-Aviles P, Torrealba D, Figueroa C, Mercado L, Dixon B, Conejeros P Front Immunol. 2022; 13:1019404.
PMID: 36466828 PMC: 9714679. DOI: 10.3389/fimmu.2022.1019404.
Current status and development prospects of aquatic vaccines.
Du Y, Hu X, Miao L, Chen J Front Immunol. 2022; 13:1040336.
PMID: 36439092 PMC: 9684733. DOI: 10.3389/fimmu.2022.1040336.
He X, Zeng Z, Wu P, Jiang W, Liu Y, Jiang J Front Immunol. 2022; 13:1027064.
PMID: 36330527 PMC: 9623247. DOI: 10.3389/fimmu.2022.1027064.
Rozas-Serri M Front Immunol. 2022; 13:856896.
PMID: 35386699 PMC: 8979166. DOI: 10.3389/fimmu.2022.856896.